Sergei Shumaster
Family Medicine · Traverse City, MINPI 1366830606
Payments from drug & device makers
Across 379 payments — averaging $14.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$883
- Pfizer$520
- GSK$518
- Lilly USA, LLC$451
- AstraZeneca$417
- Boehringer Ingelheim$413
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,316100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 57 | $883 |
| Pfizer | 36 | $520 |
| GSK | 93 | $518 |
| Lilly USA, LLC | 33 | $451 |
| AstraZeneca | 17 | $417 |
| Boehringer Ingelheim | 20 | $413 |
| Novo Nordisk | 24 | $390 |
| Amgen(2 entities) | 14 | $228 |
| Merck | 10 | $226 |
| Astellas Pharma US Inc | 13 | $198 |
| Otsuka America Pharmaceutical, Inc. | 7 | $145 |
| Exact Sciences | 7 | $129 |
| Bayer | 4 | $66 |
| Johnson & Johnson | 4 | $48 |
| Aimmune Therapeutics, Inc. | 2 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Radius Health, Inc. | 3 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Sanofi Pasteur Inc. | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Seqirus USA Inc | 2 | $35 |
| Novartis | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Indivior Inc. | 1 | $32 |
| Shield Therapeutics Inc | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Collegium Pharmaceutical, Inc. | 2 | $26 |
| Dexcom, Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Neurelis, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Abbott | 1 | $13 |
| Biogen | 1 | $12 |
| Vertiflex, Inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,316 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 69 | $108,479 |
| OzempicSemaglutide | 70 | $97,818 |
| EliquisApixaban | 89 | $90,061 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $63,975 |
| JardianceEmpagliflozin | 41 | $48,513 |
| FarxigaDapagliflozin Propanediol | 30 | $41,963 |
| TrulicityDulaglutide | 18 | $28,685 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $20,479 |
| LinzessLinaclotide | 14 | $17,273 |
| RybelsusSemaglutide | 13 | $16,197 |
| XareltoRivaroxaban | 16 | $14,752 |
| Atorvastatin Calcium | 845 | $12,740 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $12,291 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $6,724 |
| Omeprazole | 345 | $5,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $451 | $137,16487 claims |
| Novo NordiskOzempic, Rybelsus | $390 | $114,01583 claims |
| PfizerEliquis | $520 | $90,06189 claims |
| GSKTrelegy Ellipta | $518 | $63,97571 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $417 | $62,44261 claims |
| Boehringer IngelheimJardiance | $413 | $48,51341 claims |
| AbbVieLinzess, Synthroid | $883 | $19,05049 claims |
| Johnson & JohnsonXarelto | $48 | $14,75216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Traverse City
- Rafay BaigTraverse City$48K
- Kathryn ShafferTraverse City$20K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.